Plan to attend these Late-Breaking Science sessions
Learn the latest research results during these Late-Breaking Sessions.
Late-Breaking Science
LBS.01: Late-Breaking Science 1 | Celebrating a Century of Cardiovascular Science: From Prevention to Treatment, to Cure
8:30-9:45 a.m. | Saturday, Nov. 16 | Main Event I
- Effects of Intensive Blood Pressure Control in Patients With Type 2 Diabetes (BPROAD)
- Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
- Nexiguran Ziclumeran (nex-z, also known as NTLA-2001), an Investigational in Vivo CRISPR-Based Therapy for Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Interim Report of the Phase 1 Study
LBS.02: Late-Breaking Science 2 | Redefining Arrhythmia Treatment: Pushing Boundaries
1:30-2:45 p.m. | Saturday, Nov. 16 | Main Event I
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2)
- Randomized Comparison of Left Atrial Appendage Closure With Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation (OPTION)
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN AF)
LBS.03: Late-Breaking Science 3 | Smart Cardiology: Harnessing AI and Innovation for Better Heart Health
3:15-4:30 p.m. | Saturday, Nov. 16 | Main Event I
- Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study)
- Novel AI to Assess Intracardiac Filling Pressure: The Noninvasive SEISMocardiogram in Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
- Artificial Intelligence-Based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial
- PanEcho: Complete AI-enabled Echocardiography Interpretation With Multitask Deep Learning
LBS.04: Late-Breaking Science 4 | From Intervention to Prevention: Advances in Coronary and Valvular Heart Disease
8-9:15 a.m. | Sunday, Nov. 17 | Main Event I
- Efficacy of Restrictive vs. Liberal Oxygenation in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement: A Randomized Clinical Trial (GLORIOUS)
- Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement: A Randomized Clinical Trial (GLORIOUS)
- Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: ENBALV Trial
- The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine vs. Placebo and Spironolactone vs. Placebo in Patients With Myocardial Infarction: The Results of the Spironolactone Factorial
LBS.05: Late-Breaking Science 5 | Innovation in Prevention and Global Implementation
3:30-4:45 p.m. | Sunday, Nov. 17 | Main Event I
- TOPSPIN - A Three-Arm Randomized Trial for Treatment Optimization of Blood Pressure With Single-Pill Combinations In India
- Electronic Nudges to Increase Influenza Vaccination Among Patients With History of Myocardial Infarction: Insights From 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU)
- Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies After Acute Coronary Syndrome (ZODIAC)
- Preliminary Results of Randomized Trial of New vs. Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low- and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Trial
LBS.06: Late-Breaking Science 6 | Building on the Four Pillars: Novel Trials of Medical Therapy for Heart Failure
8-9:15 a.m. | Monday, Nov. 18 | Main Event I
- Myeloperoxidase Inhibition With Mitiperstat in Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Primary Results From the ENDEAVOR Randomized Clinical Trial
- Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
- Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
- Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial
LBS.07: Late-Breaking Science 7 | Revolutionizing AF Management: Cutting-Edge Approaches
9:45-11 a.m. | Monday, Nov. 18 | Main Event I
- Comparison of Linear Ablation Plus Pulmonary Vein Isolation vs. Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results From the PROMPT-AF Randomized Trial
- Cryoballoon Ablation vs. Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Noninferiority Clinical Trial
- Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
- Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial
LBS.08: Late-Breaking Science 8 | New Targets and New Treatments: Advances in Lipid Therapeutics
1:30-2:45 p.m. | Monday, Nov. 18 Main Event I
- ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks.
- A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
- Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN)
